Aficamten improves symptoms, peak VO2 in nonobstructive HCM

Aficamten was associated with improvement in heart failure symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, according to topline results of the ACACIA-HCM trial.
The results mean that aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. As Healio previously reported, the ODYSSEY-HCM trial did not show a benefit for mavacamten (Camzyos, Bristol Myers Squibb) in this population.
“Patients with nonobstructive HCM have no therapies approved to treat the underlying








